新型抗骨质疏松症生物制剂对肌肉的影响及其机制  

Influence of new anti-osteoporotic biological agents on muscle and its mechanisms

作　　者：汪艳叶 李梅 WANG Yan-ye;LI Mei(Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医学院、北京协和医院内分泌科,国家卫生健康委员会内分泌重点实验室,北京100730

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2023年第6期618-624,共7页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家重点研发计划(2018YFA0800801,2021YFC2501704);中国医学科学院医学与健康科技创新工程项目(2021-I2M-C&T-B-007,2021-I2M-1-051);国家自然科学基金面上项目(82070908);中央高水平医院临床科研业务费资助(2022-PUMCH-B-014)。

摘　　要：骨骼和肌肉受共同的遗传因素、内分泌、信号通路及力学机制相互调控,因此骨质疏松症和肌肉减少症息息相关。近年来,骨质疏松治疗药物取得长足进展,新型抗骨质疏松症生物制剂包括地舒单抗、特立帕肽及罗莫佐单抗等,能够有效增加骨密度、降低骨折风险。新近研究显示,抗骨质疏松生物制剂可能通过Wnt/β-联环素通路和核因子κB受体活化因子(receptor activator of nuclear factor kappa B,RANK)-核因子κB受体活化因子配体(receptor activator of nuclear factor-kappa B ligand,RANKL)-骨保护素(osteoprote-gerin,OPG)通路等,提高肌肉含量、增强肌力,因此可能对肌肉减少症具有潜在的益处。Osteoporosis is closely linked with sarcopenia because bone and muscle are regulated by common genetic factors,endocrine,signaling pathways and mechanical mechanisms.Recently,great progress has been made in the treatment of osteoporosis.New anti-osteoporotic biological agents,such as denosumab,teriparatide,and romosozumab,can effectively increase bone mineral density and reduce the risk of fracture.Recent studies indicate that new anti-osteoporotic biological agents may improve muscle mass and muscle strength through Wnt/β-catenin pathway or RANK-RANKL-OPG pathway,so they may have potential benefits for sarcopenia.

关 键 词：骨质疏松症 肌肉减少症 新型抗骨质疏松生物制剂 

分 类 号：R681[医药卫生—骨科学] R453[医药卫生—外科学]